Biotech News
Related news
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-06-23 13:00 EST
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
ALGSAligos Therapeutics2026-07-13 12:00 EST
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
SGMTSagimet Biosciences2026-08-25 11:00 EST
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LXRXLexicon Pharmaceuticals2026-07-27 12:30 EST
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
SGMTSagimet Biosciences2026-09-28 11:00 EST
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
VANIVivani Medical2026-08-06 12:00 EST
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
RYTMRhythm Pharmaceuticals2026-06-12 20:01 EST
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Stock data
- Close
- 3.95 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States